Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.88%
1,100.61
-9.73
-0.88%
—1,110.341,110.371,117.241,097.84——
SIXC
Communications
SIXC
Communications
SIXC
-1.33%
612.30
-8.24
-1.33%
—620.54620.54622.67611.42——
SIXE
Energy
SIXE
Energy
SIXE
+1.40%
1,175.46
+16.26
+1.40%
—1,159.201,160.591,177.621,156.21——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.39%
1,729.12
-24.32
-1.39%
—1,753.441,749.081,762.011,724.74——
SIXM
Financials
SIXM
Financials
SIXM
-0.63%
644.73
-4.07
-0.63%
—648.80649.58655.73643.68——
SIXR
Staples
SIXR
Staples
SIXR
-0.65%
827.09
-5.40
-0.65%
—832.49832.07833.09826.15——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-1.98%
214.82
-4.34
-1.98%
—219.16219.16219.19214.82——
SIXT
Technology
SIXT
Technology
SIXT
+0.06%
3,115.17
+1.81
+0.06%
—3,113.363,120.793,143.643,105.16——
SIXU
Utilities
SIXU
Utilities
SIXU
-1.75%
910.43
-16.24
-1.75%
—926.67927.99930.54910.08——
SIXV
Health care
SIXV
Health care
SIXV
-1.01%
1,474.50
-15.11
-1.01%
—1,489.611,499.051,499.051,474.35——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,405.87
-17.39
-0.72%
—2,423.262,438.162,443.462,399.83——
RDY:NYSE
Dr Reddy's Laboratories Ltd
$12.77
-2.44%
(-0.32) 1D
$12.90
+1.02% (+0.13)
After hours
Closed: Apr 21, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
$13.02
High
$13.03
Low
$12.77
Mkt. cap
10.81B
Avg. vol.
2.32M
Volume
2.00
Dividend
0.72%
Quarterly dividend
$0.02
Ex dividend date
Jul 16, 2024
P/E ratio
17.51
52-wk high
$16.17
52-wk low
$12.77
EPS
$0.73
Beta
0.37
Shares outstanding
834.62M
No. of employees
28K
News stories
From sources across the web
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.8K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Websitedrreddys.com
Last report
Jan 21, 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
14.77/ (14.27 est.)INR
+3.51%beat
Revenue / Estimate
87.27B/ (84.52B est.)INR
+3.25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
85.06B
85.45B
88.05B
87.27B
Cost of goods sold
37.80B
36.82B
39.91B
40.46B
Cost of revenue
37.80B
36.82B
39.91B
40.46B
Research and development expenses
7.26B
6.24B
6.20B
6.15B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24.06B
25.65B
26.44B
26.92B
Operating expense
29.92B
31.11B
31.90B
32.48B
Total operating expenses
67.71B
67.94B
71.81B
72.94B
Operating income
17.35B
17.52B
16.24B
14.33B
Other non operating income
719.00M
-
1.28B
570.00M
EBT including unusual items
20.05B
19.05B
18.35B
15.43B
EBT excluding unusual items
19.76B
18.36B
17.81B
15.52B
Income tax expense
4.18B
4.95B
4.08B
3.53B
Effective tax rate
20.85%
25.99%
22.24%
22.90%
Other operating expenses
-1.40B
-779.00M
-740.00M
-591.00M
Net income
15.94B
14.18B
14.37B
12.10B
Net profit margin
18.74%
16.59%
16.32%
13.86%
Earnings per share
19.84
17.02
17.87
14.77
Interest and investment income
564.00M
1.13B
912.00M
796.00M
Interest expense
-656.00M
-830.00M
-907.00M
-944.00M
Net interest expenses
-92.00M
298.00M
5.00M
-148.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
20.65B
22.28B
21.29B
19.54B
Gain or loss from assets sale
-1.07B
40.00M
-308.00M
-179.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer